Yttrium (90Y) tacatuzumab tetraxetan: Difference between revisions
Content deleted Content added
Tim Q. Wells (talk | contribs) m grammar |
mNo edit summary |
||
| Line 3: | Line 3: | ||
| source = [[Human]] |
| source = [[Human]] |
||
| target = |
| target = |
||
| CAS_number = |
| CAS_number = 476413-07-7 |
||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| DrugBank = |
| DrugBank = |
||
| chemical_formula = C<sub>6470</sub>H<sub>9971</sub>N<sub>1712</sub>O<sub>2007</sub>S<sub>42</sub><sup>90</sup>Y |
|||
| chemical_formula = |
|||
| molecular_weight = |
| molecular_weight = |
||
| bioavailability = |
| bioavailability = |
||
Revision as of 08:43, 12 July 2007
Tacatuzumab tetraxetan is a humanized monoclonal antibody used to treat cancer. Tacatuzumab has a chelator, tetraxetan. It has a radioisotope, yttrium-99Y.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |